Impact of the OBBBA Act's $1 Trillion Medicaid Cuts on Rare Disease Biotech Investments, Including Sarepta
Introduction of the OBBBA Act and Large-Scale Reduction in Medicaid Funding
The 'One Big Beautiful Bill Act' (OBBBA), signed by the Donald Trump administration, is scheduled to take full effect on January 1, 2027, bringing significant changes to the U.S. healthcare system. This act reduces Medicaid funding by approximately $1 trillion over the next 10 years and mandates nationwide work requirements and mandatory eligibility re-evaluations every six months. The Kaiser Family Foundation (KFF) estimates that this will result in approximately 17 million people losing their health insurance coverage. This not only reduces healthcare access for patients who rely on public health insurance but also poses a direct risk to the public insurance-based revenue structure of biotech companies in the long term.
High Medicaid Dependence and Market Contraction in Rare Disease Treatments
The rare disease and pediatric therapeutics sector is particularly heavily reliant on Medicaid funding. Companies like Sarepta Therapeutics, with its Duchenne Muscular Dystrophy (DMD) treatment Elevidys (delandistrogene moxeparvovec), and Novartis, with its Zolgensma (onasemnogene abeparvovec), have a significant portion of their pediatric patient prescriptions covered by Medicaid. In fact, Medicaid spending on rare disease treatments has grown rapidly from $148.3 million in 2017 to $879.7 million in 2022. The reduction in Medicaid coverage will limit patients' access to expensive innovative drugs, which could significantly reduce the commercial viability of these companies.
Concerns about Disruption of Clinical Trial Patient Recruitment and Early Diagnosis Data
The loss of insurance coverage will not only reduce revenue but also create significant bottlenecks in clinical trials, which are essential for drug development. The loss of public insurance eligibility will limit patients' access to primary care, making it impossible to accurately diagnose and identify patients with rare diseases. According to EveryLife Foundation for Rare Diseases, a non-profit organization, sophisticated insurance databases and medical records are essential assets that help clinical trial sponsors quickly and efficiently recruit suitable patients. If Medicaid cuts reduce the visibility of data on the patient pool, the speed of clinical trial recruitment may slow down, operating costs may increase significantly, and the overall drug development cycle may be prolonged.
Avoidance of Venture Capital Investment and Strengthening of Risk Management
If this policy uncertainty continues, the sentiment of investors participating in the biotech fundraising market will inevitably cool down. Aviva Strategies, a healthcare consulting firm, points out that the reduction in insurance coverage could stimulate risk aversion in the capital markets, leading to a decline in venture capital (VC) funding for early-stage pipelines and pediatric disease areas. Although the OBBBA Act provides incentives by permanently extending domestic research and development (R&D) tax credits and easing the requirements for rare drug price reductions under the Inflation Reduction Act (IRA), concerns about the shrinking commercial market outweigh these benefits. As a result, small and medium-sized biotech companies will adopt more conservative financial strategies, such as accelerating asset licensing to large pharmaceutical companies in the early stages of development to diversify risk.
The $1 trillion Medicaid funding cut under the OBBBA Act will act as a short-term negative factor that fundamentally undermines the commercial viability of rare disease and pediatric disease-focused biotechs such as Sarepta Therapeutics. In particular, given the high proportion of high-priced gene therapies (worth approximately $2.1 million) such as Spinraza and Zolgensma that are billed to Medicaid, the loss of insurance coverage for approximately 17 million people will directly reduce market size and lead to downward revisions in revenue forecasts. In the medium to long term, the lack of insurance data will extend the recruitment period for clinical trial (Phase 1-3) subjects and increase development costs, reducing the attractiveness of next-generation gene therapy pipelines for fundraising. Despite the permanent extension of R&D tax credits and the strengthening of IRA rare drug price exemption regulations, venture capital (VC) aversion to healthcare investment is expected to increase the reliance of early-stage biotech startups on licensing agreements (L/O).